July 12, 2022 | Pharma, clinical trials, innovative trials, patient recruitment, pharmaceutical
COVID-19 has hugely affected clinical trials and patient recruitment, with the entire industry on hold for some time causing backlogs and delays most of the studies.
In a recent webinar Kate Shaw,Innovative Trials’ Founder & CEO, Whitney Taynton, Unit Head at Innovative Trials, and Jane Thurston, Senior Patient Recruitment Lead for Parexel, discussed strategies for accelerating patient recruitment in clinical trials post-COVID-19 that will satisfy both sites and sponsors.
Read more here
This content was provided by Innovative Trials
Company Details
Latest Content from Innovative Trials
Kate Shaw comments on the latest news about AstraZeneca and Merck’s decision to hold planned investments in the UK
Boosting screening & enrollment rates in a global oncology trial
Clinical trial patient recruitment and retention practices have significantly advanced over the last 15 years thanks to technological innovations and the rise of AI, shifting patient expectations and the increased,…
Artificial intelligence (AI) in clinical research has the potential to accelerate patient access to new treatments by streamlining the drug development process and helping to generate more robust data, which…
So far this year, we have witnessed several announcements that could have a major impact on the clinical trials market and our global health overall.
Innovative Trials, an internationally renowned clinical trials patient recruitment company based in the UK, has today announced Garden House Hospice Care as its UK charity partner for 2025/26. It continues…
Kate Shaw, founder and CEO of Innovative Trials, has responded to data that shows the UK has far fewer women-only clinical trials compared to male-only studies. Read the full article here.
Join Innovative Trials and Soglia in this new patient recruitment and retention webinar!
🎉 Cheers to 15 years of patient recruitment and retention innovation and impact at Innovative Trials! 🎉 From 2010 to 2025, we’ve been on an incredible journey of growth, impact,…
John Watkinson is the new Non-Exec Chair as Innovative Trials targets significant business growth
